Carolyn Rosner

Carolyn Rosner

Auto-generated profile, based on publicly available information

Carolyn Rosner

Department of Cardiovascular Disease, Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, Virginia, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
CRCarolyn M. Rosner
Carolyn M. Rosner
LGLeonard Genovese
Leonard Genovese
BTBehnam N. Tehrani
Behnam N. Tehrani
MAMelany Atkins
Melany Atkins
HBHooman Bakhshi
Hooman Bakhshi
CDChristopher R. Defilippi
Christopher R. Defilippi
Supplemental Digital Content is available in the text.

5 May 2022 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
SSShashank S. Sinha
Shashank S. Sinha
CRCarolyn M. Rosner
Carolyn M. Rosner
BTBehnam N. Tehrani
Behnam N. Tehrani
AMAneel Maini
Aneel Maini
ATAlexander G. Truesdell
Alexander G. Truesdell
WBWayne Batchelor
Wayne Batchelor
Background: Little is known about clinical characteristics, hospital course, and longitudinal outcomes of patients with cardiogenic shock (CS) related to heart failure (HF-CS) compared to acute myocardial infarction (AMI; CS related to AMI [AMI-CS]). Methods: We examined in-hospital and 1-year outcomes of 520 (219 AMI-CS, 301 HF-CS) consecutive patients with CS (January 3, 2017–December 31, 2019) in a single-center registry. Results: Mean age was 61.5±13.5 years, 71% were male, 22% were Black patients, and 63% had chronic kidney disease. The HF-CS cohort was younger (58.5 versus 65.6 years, P <0.001), had fewer cardiac arrests (15.9% versus 35.2%, P <0.001), less vasopressor utilization (61.8% versus 82.2%, P <0.001), higher pulmonary artery pulsatility index (2.14 versus 1.51, P <0.01), lower cardiac power output (0.64 versus 0.77 W, P <0.01) and higher pulmonary capillary wedge pressure (25.4 versus 22.2 mm Hg, P <0.001) than patients with AMI-CS. Patients with HF-CS received less temporary mechanical circulatory support (34.9% versus 76.3% P <0.001) and experienced lower rates of major bleeding (17.3% versus 26.0%, P= 0.02) and in-hospital mortality (23.9% versus 39.3%, P <0.001). Postdischarge, 133 AMI-CS and 229 patients with HF-CS experienced similar rates of 30-day readmission (19.5% versus 24.5%, P =0.30) and major adverse cardiac and cerebrovascular events (23.3% versus 28.8%, P =0.45). Patients with HF-CS had lower 1-year mortality (n=123, 42.6%) compared to the patients with AMI-CS (n=110, 52.9%, P =0.03). Cumulative 1-year mortality was also lower in patients with HF-CS (log-rank test, P =0.04). Conclusions: Patients with HF-CS were younger, and despite lower cardiac power output and higher pulmonary capillary wedge pressure, less likely to receive vasopressors or temporary mechanical circulatory support. Although patients with HF-CS had lower in-hospital and 1-year mortality, both cohorts experienced similarly high rates of postdischarge major adverse cardiovascular and cerebrovascular events and 30-day readmission, highlighting that both cohorts warrant careful long-term follow-up. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03378739.

8 June 2022 in JACC: Heart Failure
Verified
Journal Article
Closed access
BTBehnam N. Tehrani
Behnam N. Tehrani
MSMatthew W. Sherwood
Matthew W. Sherwood
CRCarolyn Rosner
Carolyn Rosner
ATAlexander G. Truesdell
Alexander G. Truesdell
SLSeiyon Ben Lee
Seiyon Ben Lee
WBWayne Batchelor
Wayne Batchelor

4 April 2023 in US Cardiology Review
Verified
Journal Article
Open access
PDF file
ATAlexander G Truesdell
Alexander G Truesdell
RDRhian Davies
Rhian Davies
MEMoemen Eltelbany
Moemen Eltelbany
MMMichael Megaly
Michael Megaly
CRCarolyn Rosner
Carolyn Rosner
LCLindsey A Cilia
Lindsey A Cilia
Technological and procedural innovations presently permit the safe and effective performance of increasingly complex percutaneous coronary interventions, while new mechanical circulatory support devices offer circulatory and ventricular support to patients with severely reduced left ventricular systolic function and deranged cardiovascular hemodynamics. Together, these advances now permit the application of complex percutaneous coronary interventions to higher-risk patients who might otherwise be left untreated. Increasing observational data support the use of mechanical circulatory support in appropriate complex and high-risk patients as part of a larger multidisciplinary heart team treatment plan. In-progress and upcoming randomized clinical trials may provide higher-quality evidence to better guide management decisions in the near future.

22 November 2021 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
APAlastair G. Proudfoot
Alastair G. Proudfoot
AKAntonis Kalakoutas
Antonis Kalakoutas
SMSusanna Meade
Susanna Meade
MGMark J.D. Griffiths
Mark J.D. Griffiths
MBMir Babar Basir
Mir Babar Basir
PIPeter M. Irving
Peter M. Irving
Background: Current practice in cardiogenic shock is guided by expert opinion in guidelines and scientific statements from professional societies with limited high quality randomized trial data to inform optimal patient management. An international panel conducted a modified Delphi process with the intent of identifying aspects of cardiogenic shock care where there was uncertainty regarding optimal patient management. Methods: An 18-person multidisciplinary panel comprising international experts was convened. A modified RAND/University of California Los Angeles appropriateness methodology was used. A survey comprising 70 statements was completed. Participants anonymously rated the appropriateness of each statement on a scale of 1 to 9: 1 to 3 inappropriate, 4 to 6 uncertain, and 7 to 9 appropriate. A summary of the results was discussed as a group, and the survey was iterated and completed again before final analysis. Results: There was broad alignment with current international guidelines and consensus statements. Overall, 44 statements were rated as appropriate, 19 as uncertain, and 7 as inappropriate. There was no disagreement with a disagreement index <1 for all statements. Routine fluid administration was deemed to be inappropriate. Areas of uncertainty focused panel on pre-PCI interventions, the use of right heart catheterization to guide management, routine use of left ventricular unloading strategies, and markers of futility when considering escalation to mechanical circulatory support. Conclusions: While there was broad alignment with current guidance, an expert panel found several aspects of care where there was clinical equipoise, further highlighting the need for randomized controlled trials to better guide patient management and decision making in cardiogenic shock.

21 February 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
NBNarotham Badrish
Narotham Badrish
SSStuart Sheifer
Stuart Sheifer
CRCarolyn M. Rosner
Carolyn M. Rosner
Heart failure (HF) represents a worldwide health burden and the annual per patient cost to treat HF in the US is estimated at $24,383, with most of this expense driven by HF related hospitalizations. Decompensated HF is a leading cause for hospital admissions and is associated with an increased risk of subsequent morbidity and mortality. Many hospital admissions for decompensated HF are considered preventable with timely recognition and effective intervention.Systems of care that include interventions to facilitate early recognition, timely and appropriate intervention, intensification of care, and optimization to prevent recurrence can help successfully manage decompensated HF in the ambulatory setting and avoid hospitalization.